GlassScriptPhysician profile
Jacob Alexander Bair
NPI 1346597523
$23,753.68
in general payments reported to CMS, 2019-2025
43 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,695 · 2020: $1,542 · 2021: $2,882 · 2022: $3,083 · 2023: $3,125 · 2024: $2,971 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,550.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedplasma LLC | $8,318.75 | 2019 | |
| Abbvie INC. | $3,590.93 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $2,358.38 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,161.36 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $1,095.79 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $724.73 | 2019-2024 | |
| Amarin Pharma, INC. | $595.02 | 2019-2023 | |
| Daiichi Sankyo INC. | $491.31 | 2019-2023 | Injectafer |
| Amgen INC. | $490.97 | 2019-2024 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $486.22 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $468.98 | 2019-2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $394.68 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $283.52 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $275.25 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.79 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $253.60 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.18 | 2020-2023 | Jardiance, Tradjenta |
| Allergan, INC. | $238.87 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $191.89 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $191.40 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $171.25 | 2019-2022 | |
| Exact Sciences Corporation | $159.02 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $155.31 | 2019-2023 | |
| Abbott Laboratories | $131.67 | 2022-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $130.25 | 2019-2023 | Verquvo, Steglatro |
| Nestle Healthcare Nutrition INC. | $111.71 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $99.27 | 2021-2024 | Camzyos, Eliquis |
| Astellas Pharma US INC | $81.93 | 2024 | Veozah |
| Endo Pharmaceuticals INC. | $75.32 | 2020-2021 | |
| Corium, LLC | $68.31 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $58.91 | 2023-2024 | Auvelity |
| Horizon Therapeutics Plc | $55.38 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $47.71 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $40.93 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $39.96 | 2023-2024 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $38.87 | 2020-2024 | |
| Ibsa Pharma INC. | $35.42 | 2023 | Tirosint, Licart |
| Jazz Pharmaceuticals INC. | $32.03 | 2019-2020 | |
| Lundbeck LLC | $27.76 | 2022-2024 | Rexulti |
| Genentech USA, INC. | $17.05 | 2020 | |
| Collegium Pharmaceutical, INC. | $16.86 | 2022 | |
| Shield Therapeutics INC | $16.31 | 2023 | Accrufer |
| Tris Pharma INC | $14.83 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Bair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.